Dr. Christopher Joseph Devine, President, Devine Guidance International
Devine Guidance

IVDD Article 21 – Amendment of Directives

By Dr. Christopher Joseph Devine
Dr. Christopher Joseph Devine, President, Devine Guidance International

Although Article 21 of the IVDD does not directly influence the Directive, “changes are coming,” so please stay tuned.


Article 21 (Amendment of Directives) of the IVDD (98/79/EC) delineates changes to Directives approved by the Commission. The good news is that although the Amendment of Directives is embedded in the IVDD, under Article 21, there are no amendments actually being made to the IVDD.

The bad news is that significant changes to the IVDD are coming. For those readers familiar with the IVDD, I am sure you have asked yourselves why bother inserting an Article that has no direct relevance? The answer is because the regulatory gods in the EU believed there was value providing pointers to changes made to the MDD (93/42/EEC); and the old Machinery Directive (98/37/EC).

To complicate matters, 98/37/EC was replaced by Directive 2006/42/EC in December of 2009. For readers familiar with the MDD, the MDD has its own Article 21 “Repeal and Amendment of Directives.” Guess what? Article 21 of the MDD and Article 21 of the IVDD do not necessarily match. Thank God 90/385/EEC (the AIMDD) does not contain an Article 21, it stops at Article 17. Confused? Good, join the club. That being said, Dr. D’s advice to the readers of Devine Guidance is to ensure you perform an exegesis (look-it-up) review of the IVDD in support of understanding all of the Directive’s nuances while achieving or sustaining compliance. 

The IVDD – 98/79/EC
Article 21 – Amendment of Directives
1. In Directive 98/37/EC, the second indent of Article 1(3), ‘machinery for medical use, used in direct contact with patients’ shall be replaced by the following: ‘— medical devices,’
2. Directive 93/42/EEC is hereby amended as follows:
(a) in Article 1(2):
— point (c) shall be replaced by the following: ‘(c) “in vitro diagnostic medical device” means any medical device which is a reagent, reagent product, calibrator, control material, kit, instrument, apparatus, equipment or system, whether used alone or in combination, intended by the manufacturer to be used in vitro for the examination of specimens, including blood and tissue donations, derived from the human body, solely or principally for the purpose of providing information:
  • concerning a physiological or pathological state, or
  • concerning a congenital abnormality, or
  • to determine the safety and compatibility with potential recipients, or
  • to monitor therapeutic measures.
Specimen receptacles are considered to be in vitro diagnostic medical devices. “Specimen receptacles” are those devices, whether vacuum-type or not, specifically intended by their manufacturers for the primary containment and preservation of specimens derived from the human body for the purpose of in vitro diagnostic examination. 
Products for general laboratory use are not in vitro diagnostic medical devices unless such products, in view of their characteristics, are specifically intended by their manufacturer to be used for in vitro diagnostic examination;’
— point (i) shall be replaced by the following: ‘(i) “putting into service” means the stage at which a device has been made available to the final user as being ready for use on the Community market for the first time for its intended purpose;’
— the following point shall be added: ‘(j) “authorized representative” means any natural or legal person established in the Community who, explicitly designated by the manufacturer, acts and may be addressed by authorities and bodies in the Community instead of the manufacturer with regard to the latter’s obligations under this Directive;’
(b) Article 2 shall be replaced by the following:
— ‘Article 2 Placing on the market and putting into service: Member States shall take all necessary steps to ensure that devices may be placed on the market and/or put into service only if they comply with the requirements laid down in this Directive when duly supplied and properly installed, maintained and used in accordance with their intended purpose.’ 
(c) the following paragraph shall be added to Article 14(1): ‘For all medical devices of classes IIb and III, Member States may request to be informed of all data allowing for identification of such devices together with the label and the instructions for use when such devices are put into service within their territory.’
(d) the following Articles shall be inserted: 
— ‘Article 14a European databank
1. Regulatory data in accordance with this Directive shall be stored in a European database accessible to the competent authorities to enable them to carry out their tasks relating to this Directive on a well-informed basis. The databank shall contain the following:
(a) data relating to registration of manufacturers and devices in accordance with Article 14;
(b) data relating to certificates issued, modified, supplemented, suspended, withdrawn or refused according to the procedures, as laid down in Annexes II to VII;
(c) data obtained in accordance with the vigilance procedure as defined in Article 10;
2. Data shall be forwarded in a standardized format.
3. The procedures implementing this Article shall be adopted in accordance with the procedure laid down in Article 7(2).
— Article 14b Particular health monitoring measures
Where a Member State considers, in relation to a given product or group of products, that, in order to ensure protection of health and safety and/or to ensure that public health requirements are observed pursuant to Article 36 of the Treaty, the availability of such products should be prohibited, restricted or subjected to particular requirements, it may take any necessary and justified transitional measures. It shall then inform the Commission and all the other Member States giving the reasons for its decision. The Commission shall, whenever possible, consult the interested parties and the Member States and, where the national measures are justified, adopt necessary Community measures in accordance with the procedure referred to in Article 7(2).’
(e) the following paragraphs shall be added to Article 16:
5. The notified body shall inform the other notified bodies and the competent authority about all certificates suspended or withdrawn and, on request, about certificates issued or refused. It shall also make available, on request, all additional relevant information.
6. Where a notified body finds that pertinent requirements of this Directive have not been met or are no longer met by the manufacturer or where a certificate should not have been issued, it shall, taking account of the principle of proportionality, suspend or withdraw the certificate issued or place any restrictions on it unless compliance with such requirements is ensured by the implementation of appropriate corrective measures by the manufacturer. In the case of suspension or withdrawal of the certificate or of any restriction placed on it or in cases where an intervention of the competent authority may become necessary, the notified body
shall inform its competent authority thereof. The Member State shall inform the other Member States and the Commission.
7. The notified body shall, on request, supply all relevant information and documents including budgetary documents, required to
enable the Member State to verify compliance with Annex XI requirements.’
(f) the following paragraph shall be added to Article 18: ‘Those provisions shall also apply where the CE marking has been affixed in accordance with the procedures in this Directive, but inappropriately, on products that are not covered by this Directive.’
(g) in Article 22(4), the first subparagraph shall be replaced by the following:
4. Member States shall accept:
— devices which conform to the rules in force in their territory on 31 December 1994 being placed on the market during a period of five years following the adoption of this Directive, and 
— the aforementioned devices being put into service until 30 June 2001 at the latest.’
(h) Annex II, section 6.2, Annex III, section 7.1, Annex V, section 5.2 and Annex VI, section 5.2 shall be deleted;
(i) in Annex XI, section 3 the following sentence shall be inserted after the second sentence: ‘This presupposes the availability of sufficient scientific staff within the organization who possess experience and knowledge sufficient to assess the medical functionality and performance of devices for which it has been notified, having regard to the requirements of this Directive and, in particular, those set out in Annex I.’
What IVDD medical device manufacturers need to know
Nothing! That’s right, the doctor clearly stated, “Nothing!” However, the nothing only pertains to Article 21 in its current state. In regards to the actual IVDD, significant changes are coming with the most noticeable the addition of two additional lists under Annex II. Can you say, “Welcome List C and List D?” Additionally, the order of criticality, premised on risk, will be reversed. What in the heck does that mean Dr. D? In short, List A devices will migrate to the newly created List D. The revised List A will contain lower risk devices. 
Now just in case you are wondering, some innocuous changes to the IVDD were approved this past December. Commission Directive 2011/100/EU (20 December 2011) incorporated “Variant Creutzfeldt-Jakob Disease (vCJD)” to Annex II, List A. Commission Decision 2011/869/EU (20 December 2011) amended Common Technical Specifications for in-vitro diagnostic medical devices, incorporating vCJD assays for blood screening, diagnosis and confirmation. Trust Dr. D when I say, “These changes are benign compared to what is coming.”  
What IVDD medical device manufacturers need to do
As currently drafted, Article 21 does not have any effect on the IVDD. So in the short-term, Dr. D will once again use the term, “nothing!” That’s right; manufacturers of IVDDs have nothing to do in regards to Article 21. However, I am sure the doctor is not telling the readers anything new when I write that keeping abreast with regulatory changes, influencing the Device industry in Europe, is a fulltime job. As the doctor stated earlier in this week’s guidance, upcoming changes to the IVDD will make everyone’s life interesting, to say the least. The best guidance Dr. D can provide is to ensure each of you remain in close contact with your notified bodies. Competent notified bodies such as BSI, TUV-R, TUV-SUD, SGS, DEKRA, etc. will be able to help device manufacturers successfully navigate through the upcoming changes to the IVDD.
The takeaway from this edition of DG is eloquently simple, “Changes to the IVDD are coming.” Although Article 21 of the IVDD does not directly influence the Directive, “changes are coming.” One final thought from Dr. D (broken-record time), “changes to the IVDD are coming,” so please stay tuned.

Until the next installment of DG, when Dr. D provides insight and guidance into complying with Article 22 (Implementation, Transitional Provisions) of the In Vitro Diagnostic Medical Device Directive, a.k.a., IVDD – cheers from Dr. D and best wishes for continued professional success.


  1. Commission Decision 2011/869/EU. (2011, December). Commission decision amending decision 2002/364/EC on common technical specifications for in vitro diagnostic medical devices. Retrieved March 2, 2012, from http://eur-lex.europa.eu
  2. Commission Directive 2011/100/EU. (2011, December). Commission directive amending Directive 98/79/EC of the European Parliament and the Council on in-vitro diagnostic medical devices. Retrieved March 2, 2012,  from http://eur-lex.europa.eu.  
  3. Council Directive 90/385/EEC. (1990, June). Council Directive 90/385/EEC of 20 June 1990 on the approximation of the laws of the Member States relating to active implantable medical devices. Retrieved October 5, 2010, from http://eur-lex.europa.eu.  
  4. Council Directive 93/42/EEC. (1993, June). Council directive 93/42/EEC concerning medical devices. Retrieved March 5, 2012, from http://eur-lex.europa.eu
  5. Devine, C. (2009, July). Exploring the effectiveness of defensive-receiving inspection for medical device manufacturers: a mixed method study. Published doctoral dissertation. Northcentral University. Prescott Valley, AZ.
  6. Devine, C. (2011). Devine guidance for complying with the European medical device directive – MDD. Charleston, SC: Amazon.
  7. Devine, C. (2011). Devine Guidance series on complying with the MDD. Published in The Medical Device Summit
  8. Directive 98/79/EC. (1998, October). Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. Retrieved September 12, 2011, from http://eur-lex.europa.eu

About The Author

Dr. Christopher Joseph Devine, President, Devine Guidance International